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THE ROLE OF CYTOKINES IN IMMUNE RESPONSE TO HIV 
Mario Clerici1, Maria Luisa Villa1 and Gene M. Shearer2 
1 Cattedra Immunológia, Universita' degli Studi Milano,20133 
Milano ITALY; 2 Experimental Immunology Branch, NCI, NIH, 
Bethesda, MD,20892 U.S.A.
The mechanisms that regulate induction of distinct 
immune responses to different pathogens have recently been 
clarified by the identification in mice and man of two functionally 
distinct compartments defined as "T helper 1" (TH-1) and "T 
helper 2" (TH-2). The recognition and definition of these two 
subsets has been based on clonal isolates of purified CD4+ T 
lymphocytes. Functionally, TH-1 responses are characterized by 
secretion of IFN-yand interleukin-2 (IL-2) and subsequent 
promotion of cell mediated immunity (CMI); TH-2 responses are 
characterized by secretion of interleukin-4 (IL-4), interleukin-5 
(IL-5), interleukin-6 (IL-6), and interleukin-10 (IL-10), with 
subsequent activation of humoral immunity and generation of 
antibodies. The induction of a TH-1 response induces the 
suppression of a TH-2 response, and vice versa. This trend 
toward reciprocity is mediated through the secretion of cross- 
regulatory cytokines (IFN-y suppresses TH-2 responses; IL-4 
and IL-10 suppress TH-1 responses). These two compartments 
are differentially responsible for immune defense, and the 
preferential activation of TH-1 or TH-2 responses to agents that 
provoke disease through different mechanisms optimizes the 
immune response. Thus, the activation of a TH-1 response 
appears to be more efficient in immune defense against 
intracellular pathogens and parasites, while TH-2 responses
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may be more protective against bacterial infections and toxins. 
We have studied cytokine production profiles in HIV infection by 
in vitro stimulation of whole peripheral blood mononuclear cells 
(PBMC) of HIV seropositive (HIV+) individuals and we have 
observed that HIV infection is characterized by a switch from a 
TH-1 to a TH-2 cytokine production profile. Nevertheless, 
because our observations are based on cytokine production by 
whole PBMC and not on clonal isolation, we prefer not to use 
the clonally defined TH-1 and TH-2 terminology, but rather to 
identify the cytokine patterns observed as type 1. characterized 
by high IL-2, high IFN-y and low IL-4, low IL-10 (CMI-inducing) 
and type 2. characterized by low IL-2, low IFN-y and high IL-4, 
high IL-10 (humoral immunity-inducing).
A number of recent reports has led to the hypothesis 
that CMI, driven by the production of type 1 cytokines, might 
be associated with augmented resistance to human 
immunodeficiency virus (HIV) infection in HIV seronegative 
(HIV-) individuals exposed to HIV, and with lack of progression 
to AIDS in HIV+ individuals. Conversely, seroconversion and 
fast progression to AIDS would be associated with a prevalence 
of humoral immunity over CMI, a condition characterized by low 
production of IFN-y and IL-2, and a high production of IL-4, IL-6 
and IL-10.
To first summarize the observations that suggest how 
type 1 response may be associated with lack of progression to 
AIDS in HIV+ individuals: 1) in vitro antigen and mitogen- 
stimulated IL-2 production by peripheral blood mononuclear 
cells (PBMC) of HIV+ individuals progressively declines after 
HIV infection; this decline is accompanied by sharp increases in
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demonstrated by the observation that IL-4 knock-out mice do not 
develop MAIDS upon infection with LP-BM5.
A second line of evidences suggest that type 1 responses 
may be associated with augmented resistance to HIV infection in 
HIV- individuals. To summarize: 1) exposure to HIV in the 
absence of seroconversion is associated with the exclusive 
presence of HIV-specific T-lymphocytes, characterized as IL-2 
producing cells. HIV-specific, IL-2 producing lymphocytes have 
been detected in many individuals that do not seroconvert 
despite their belonging to groups at risk for HIV infection. These 
at-risk groups include: gay men, intravenous drugs users, sexual 
partners of HIV+ individuals, health care workers exposed to HIV 
through needle sticks, and newborns infants of HIV+ mothers. 2) 
HIV infection in newborn of HIV+ mothers is associated with 
absence of HIV specific IL-2 producing T lymphocytes. 3) CD8+ 
HLA class I restricted HIV-specific cytotoxic T lymphocytes are 
detectable in PBMC of HIV- individuals at risk for HIV infection.
4) Intrarectal exposure of macaques to different doses of simian 
immunodeficiency virus (SIV) induces seroconversion, simian 
AIDS and death only in the macaques exposed to high doses of 
SIV. SIV-specific immune responses in these macaques are 
characterized by high titers of SIV specific antibodies and weak 
or absent SIV-specific T lymphocytes. In contrast, macaques 
exposed to low doses of SIV do not seroconvert and show 
potent SIV-specific T cell responses. Additionally, these 
macaques appear to be protected upon challenge with high 
doses of SIV. 5) In a preliminary report, when PBMC from 
volunteers immunized with HIV candidate vaccines are used to 
reconstitute the deficient immune system of SCID mice, the mice
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mitogen-stimulated production of IL-4 and IL-10.The switch from 
a type 1 to a type 2 cytokine production pattern in HIV infection 
has been analyzed and confirmed at different levels: cytokine- 
specific mRNA by PCR analysis, production of cytokines by 
ELISA, and very recently, clonal isolation. 2) Defective IL-2 
production by HIV+ PBMC can be circumvented in vitro by 
stimulation of such PBMC in the presence of neutralizing 
antibodies directed toward IL-4 and/or IL-10. 3) The presence 
and the magnitude of IL-2 production defects in HIV+ 
asymptomatic individuals is predictive for the rate of decline in 
CD4 counts, time to development of AIDS, and time to death.
4) Preliminary data show that the pattern of cytokine production 
by PBMC of HIV+ long term survivors is that of a type 1 
response (high IL-2 and IFN-y; low IL-4 and IL-10). 5) Clonal 
isolates from HIV+ patients enrolled in longitudinal studies are 
initially characterized as IL-2 and IFN-y producing clones, and 
subsequently as IL-4 producing clones. 6) TH-1 and TH-2 T 
lymphocytes clones are differentially susceptible to HIV infection 
as HIV replicates only inside TH-2 clones.7) TH-1 but not TH-2 T 
lymphocytes clones are able to prevent in vitro HIV infection of 
autologous and HLA mismatched cells. Additional evidence 
supporting the hypothesis of a type 1-to-type 2 cytokine profile 
switch in HIV infection is offered by a murine model in which 
susceptible strains of mice infected with LP-BM5 murine 
leukemia virus develop an immunodeficiency syndrome defined 
murine AIDS (MAIDS). MAIDS is characterized by profound 
defects in the production of type 1 cytokines, accompanied by 
massive increases in the production of IL-4, IL-5, IL-6 and IL-10. 
That this switch is essential in the pathogenesis of MAIDS is
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are protected from challenged with HIV only if the PBMC are 
obtained from volunteers in whom the vaccine induced 
generation of HIV-specific T lymphocytes.
Thus, it seem possible that type 1 responses are more 
important than type 2 responses for successfully impeding 
infection by HIV and SIV, and may be responsible for the long 
asymptomatic period that follows HIV and SIV infection. These 
observations suggest the possibility of using cytokines based 
therapies in HIV infection with the double possible objective of 
preventing a type 1-to-type 2 switch and of restoring a type 1 
profile in those patients in which HIV infection has already 
provoked alterations in the cytokine production profile. A 
possible candidate for cytokine based therapy of HIV infection is 
interleukin 12 (IL-12). This newly described lymphokine has 
several powerful functional properties, most interestingly its 
ability to alter the T cell cytokine balance in favor of type 1 
cytokines with subsequent enhancement of CMI. Therefore, 
even if IL-12 cannot be defined as a TH-1 cytokine because it is 
not produced by T lymphocytes, IL-12 is a type 1 cytokine. As 
predicted by the type-1-to-type-2 cytokine production switch in 
HIV infection, IL-12 production is severely defective in HIV+ 
individuals when compared to HIV- controls. We recently 
described the ability of IL-12 to restore defective in vitro antigen- 
stimulated T cell proliferation and IL-2 production, and defective 
mitogen-stimulated IFN-y generation in HIV+ individuals. 
Furthermore, preliminary data suggest that IL-12 is capable of 
preventing the development of MAIDS in susceptible mice 
infected with LP-BM5.
9
Finally, cytokines based therapy of HIV infection could 
theoretically be based upon three different approaches: 1) use 
of type 1 cytokines (IFN-7; IL-2; IL-12); 2) use of anti-type 2 
neutralizing antibodies (anti-IL-4; anti-IL-10); and 3) use of 
soluble type 2 cytokines receptors (soluble IL-4 receptor). The 
clinical feasibility and the therapeutical usefulness of each one 
of these approaches will hopefully be soon evaluated in 
controlled clinical trials.
M.C and M.L.V are supported by grants from Istituto 
Superiore di Sanita' "VI Progetto AIDS 1993/VII Progetto 
AIDS 1994".
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AUTOANTIBODIES AGAINST CD4+ LYMPHOCYTES IN HIV- 
INFECTED HEMOPHILIA PATIENTS
Volker Dmiiel^, Caner Siisal*, Rolf Weimer^, Marianne 
Kröpelin , Silvia Z ipperle , Rainer Zimmermann , Angela Huth- 
Kiihne , and Gerhard Opelz1
1 Department o f Transplantation-Immunology. Institute o f 
Immunology, University o f Heidelberg, and ^Rehabilitation 
Hospital and Hemophilia Center, Heidelberg, Germany
The pathogenesis o f the CD4 +  lymphocyte depletion in H IV - 
infected patients is poorly understood. The direct cytotoxic 
effect o f H IV  on the CD4-t- lymphocytes, the capability o f H IV - 
infected cells to form syncytia and the hyperglutamataemia o f 
the patients do not explain this phenomenon completely. 
Autoimmune mechanisms, especially autoreactive T 
lymphocytes and autoantibodies gain increasing relevance for 
the conception of the AIDS pathogenesis. In this review we 
report on our autoantibody studies.
Autoantibodies may be cell-depleting or, alternatively, 
immunoregulatory. Depleting autoantibodies have their targets 
on the surface of the CD4+ lymphocytes. Regulatory 
autoantibodies, however, are antiidiotypic and react with other 
components o f the immune network that have itself regulating or 
effector function. We studied both types o f autoantibodies in 
HIV-infected hemophilia patients.
The major target structure on CD4+ lymphocytes for 
autoantibodies should be the CD4 receptor itself. Recombinant 
CD4 serves as a model for the native CD4 receptor. Antibodies 
against recombinant CD4 are found in 22% of the AIDS/ARC 
patients, 10% of the asymptomatic H IV  +  and 17% o f the H IV - 
hemophilia patients but only in 1 % o f the healthy controls tested 
in parallel (1). Antibodies against recombinant CD4 purified by 
affinity chromatography do not react with CD4+ lymphocytes o f 
healthy individuals. Because these antibodies do not recognize 
native CD4 it is not surprising that the occurrence o f antibodies 
against recombinant CD4 is not associated with the CD44- cell 
counts in the blood o f the patients (1). Another target structure 
on CD4+ lymphocytes are MHC class II antigens. Activated 
CD4+ lymphocytes express MHC class II antigens on the 
surface. The majority o f our HIV-infected hemophilia patients
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have cold reactive В lymphocyte antibodies with postulated 
M H C  class II antigen specificity (2).
Antibodies that coat C D 4+  lymphocytes in-vivo may be of 
preferential relevance for the AIDS pathogenesis. With 
flowcytometry we are able to detect immunoglobulin covered 
C D 4 +  lymphocytes in the blood of the patients (3). We 
characterized the isotype and the complement activation 
capacity o f the autoantibodies and found diverse autoantibody 
patterns on CD4+ lymphocytes. The diverse autoantibody 
patterns were associated w ith the CD4+ cell counts in the blood 
and seem to be typical for the different clinical stages o f the 
disease. A t the beginning o f the disease IgM  autoantibodies 
were found on CD4+ lymphocytes. When additional 
complement-fixing autoantibodies were detectable on the CD4 + 
lymphocytes, the CD4+ cell count decreased further on. Finally, 
at very low  CD4+ cell counts o f < 100/ul, attached gpl20 is 
demonstrable on the C D 4+  cells (4). Obviously, the immune- 
complex covered CD4+ cells are reduced by phagocytosis, 
antibody-dependent cellular cytotoxicity, cytotoxic T 
lymphocytes or antibody dependent complement dependent 
lysis.
The immune-complex load o f the CD4+ lymphocytes induces 
also impaired T lymphocyte function. Patients with 
immunoglobulin coated C D 4 +  lymphocytes in the blood 
showed an impaired T helper cell function for the T cell 
dependent В lymphocyte response in vitro (5). When soluble 
gp l20  is found on the C D 4+  lymphocytes the global mitogenic 
and allogeneic response o f the lymphocytes in-vitro decreases 
with the growing immune-complex load of the CD4 +  
lymphocytes (6). As a consequence of the T lymphocyte 
dysfunction, the monocyte/macrophage activity in-vivo 
increases and the serum neopterin levels raise (6).
Beside the autoantibodies detectable on CD4+ lymphocytes 
other autoantibody types in the serum that are both 
crossreactive with epitopes on C D 4+ lymphocytes and reactive 
with other immunoglobulins or antiidiotypic components o f the 
immune network seem to have a role in the AIDS pathogenesis. 
These antibodies may be both depletion-inducing and immuno- 
regulatory. For example, antibodies directed against the Fab 
part o f immunoglobulins can have both qualities.
The titers o f IgG-anti-Fab and IgA-anti-Fab autoantibodies were 
associated with the clinical course o f the patients. Both IgG-anti-
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Fab and IgA-anti-Fab autoantibodies were significantly 
correlated with the CD4+ lymphocyte counts o f the patients.
The IgA-anti-Fab autoantibodies were also associated with the 
serum neopterin levels (7-10).
Anti-Fab antibodies may influence the CD4+ cell counts by 
binding to C D 4+ lymphocytes. Anti-Fab antibodies from H IV  +  
sera purified by affinity chromatography reacted with CD4 +  
lymphocytes o f healthy individuals that were preincubated with 
recombinant gp 120 (9). Patients with high IgG-anti-F(ab’)2y 
antibody titers showed both high titers o f anti-gpl20 antibodies 
and high titers o f antibodies directed against the CHI domain o f 
IgG (10). Obviously, these autoantibodies that are primarily 
directed against the CHI domain are induced by circulating 
gpl20. It seems that they are able to intensify the depletion o f 
the CD4+ lymphocytes by binding to gpl20 coated CD4 +  
lymphocytes.
Conceivably, the anti-Fab antibodies regulate the immune- 
system by interaction with other antibodies and components o f 
the immune network. Sequential studies o f H IV +  patients 
showed similar titers o f anti-anti-gpl20 and anti-recombinant- 
CD4 antibodies. When H IV +  patients were grouped according 
to their C D4+ lymphocyte counts in the blood, the IgG-anti-anti- 
gpl20 titers o f the different groups paralleled the IgG-anti-anti- 
CD8 and anti-recombinant-CD4 antibody titers whereas IgG- 
anti-Fab titers showed an opposite behaviour (11). It is known 
that Fab binds recombinant CD4, CD8 binds MHC I, and CD4 
binds МНС II and gpl20. Based on these interactions, the 
existence o f two biologically distinct groups o f molecules w ith 
similarities to MHC I (anti-Fab, anti-CD8, CD4) or МНС II (gpl20, 
Fab, anti-anti-gpl20, anti-anti-CD8, anti-recombinant-CD4, CD8) 
can be hypothesized. Disturbances o f the equilibrium between 
group I and group II autoantibodies appears to play a role in the 
progression o f the disease.
Our data support the hypothesis that autoimmune mechanisms 
contribute to the CD4-I- lymphocyte dysfunctions and to the 
CD4 +  lymphocyte depletion in HIV-infected individuals. The 
autoimmune mechanisms are triggered by HIV and in part by 
soluble H IV proteins, especially gpl20.
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THE ROLE OF A CYSTEINE AND GLUTATHIONE 
DEFICIENCY IN THE IMMUNOPATHOLOGY OF HIV 
INFECTION
Dröge, W., Eck, H.-P., Mihm, S., Roth, S., Kinscherf, R., and 
Fischbach, T.
Division o f Immunochemistry, Deutsches Krebsforschungszentrum, 
D-69120 Heidelberg, Germany
A  large body o f evidence from clinical studies and complementary 
laboratory experiments indicates that the acquired immunodeficiency 
syndrome (AIDS) may be the consequence of a virus-induced 
cysteine and glutathione (GSH) deficiency (1-3). HIV-infected 
persons o f all stages o f the disease have, on the average, markedly 
decreased plasma cystine and cysteine concentrations, decreased 
intracellular glutathione and elevated plasma glutamate levels (4-6). 
Elevated extracellular glutamate levels aggravate the cysteine 
deficiency, since glutamate inhibits competitively the membrane 
transport o f cystine (7,8). Lymphocyte functions in vitro  are 
augmented even by moderate elevations o f extracellular cysteine and 
inhibited by elevation o f the extracellular glutamate concentration. A  
significant correlation between individual CD4+ T cell numbers and 
individual cystine and glutamate levels has also been found in a 
cohort o f HIV-infected persons, in healthy human blood donors and 
in chimpanzees (6,9). CD8+ T cells showed no significant correlation. 
A  rapid and significant decrease o f plasma cysteine levels, 
intracellular glutathione levels and an increase of plasma glutamate 
levels was also found in rhesus macaques 2 weeks after infection with 
the closely related SIVmac25i ,  but not in HIV-infected chimpanzees 
or SIVagm-infected African green monkeys (9,10). The latter two 
species do not develop AIDS-like symptoms. Elevated plasma 
glutamate levels were found to be negatively correlated with 
lymphocyte functions and survival time also in patients with 
advanced malignancies (6,11,12).
One important consequence o f a cysteine deficiency is the decrease o f 
intracellular glutathione and glutathione disulfide levels. There is 
now a wealth o f experimental evidence indicating that the T  cell 
system is profoundly influenced even by relatively moderate changes 
o f the extracellular cysteine concentration and the intracellular 
glutathione and glutathione disulfide levels. The limiting role o f 
cysteine is mainly the consequence o f the weak cystine transport 
activity o f lymphocytes and the relatively low extracellular 
concentrations o f reduced cysteine in blood plasma or cell cultures 
(5,8,13). In vivo, this limited and well regulated supply o f cysteine 
may be required mainly in order to ensure a well balanced 
intracellular GSSG level that allows the optimal activation of
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immunologically important NFxB-dependent genes (14-16). 
Suboptimal GSSG levels constrain the activation of nuclear 
translocation of the transcription factor NFk B, while superoptimal 
levels o f GSSG constrain its transactivating potential by inhibiting its 
DNA binding activity. In healthy human subjects, the cysteine supply 
and intracellular glutathione levels of lymphocytes appear to be 
adjusted to the optimum, since mean and median glutathione levels 
are associated with maximum T cell numbers (17). Even a moderate 
decrease or increase o f intracellular glutathione levels is associated 
with a detectable decrease o f CD4+ T cell numbers in seemingly 
healthy human subjects (17). It is, therefore, not surprising that the 
strongly decreased intracellular glutathione levels in HIV-infected 
patients are associated with a marked depletion o f the CD4+ T cell 
pool.
The more detailed analysis has finally shown that different 
immunological functions have clearly distinct requirements for 
cysteine and glutathione and that T cell responses against a strong 
mitogenic stimulus have a stronger requirement for cysteine and 
glutathione against a weak stimulus (8,18-24). This leads to the 
prediction that T cells that are constantly stimulated by environmental 
pathogens or superantigens may be more strongly affected by the 
glutathione deficiency in HIV-infected patients than T cells of other 
specificities.
Finally, we have shown that activated macrophages have a strong 
capacity to take up cystine, to release reduced cysteine into the 
extracellular space and to increase thereby the intracellular 
glutathione levels o f activated T lymphocytes in their vicinity (7,18). 
This "cysteine pumping function" of the macrophages is expectedly 
strongly inhibited by elevated extracellular glutamate levels which 
competitively inhibit the membrane transport o f cystine (7). The 
elevated plasma glutamate levels in H IV  infected patients are 
therefore expected to inhibit also certain important macrophage 
functions.
In view o f the established cysteine and glutathione deficiency in HIV 
infected persons, we have proposed to consider N-acetyl-cysteine for 
the treatment of these patients (1,25). NAC is a well established and 
safe drug with well documented toxicology and pharmacokinetics. A  
placebo controled study on healthy human subjects revealed that 
persons who moved during a 4-week observation period from the 
optimal to the suboptimal range of intracellular glutathione levels 
experienced, on the average, a 30% decrease o f CD4+ T cell numbers. 
This decrease was prevented by treatment w ith N-acetyl-cysteine 
(NAC) (17). Importantly, NAC was found to cause a relative increase 
of CD4+ T  cell numbers in spite of decreasing glutathione levels and
18
not by increasing the glutathione level. Taken together, our studies 
suggested that the immune system may be exquisitely sensitive not 
only against a cysteine and glutathione deficiency but also against an 
excess of cysteine.
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NEOPTERIN AND HIV INFECTION
Dietmar Fuchs, Robert Zangerle#, Christian Murr, 
Manfred P.Dierich*, Helmut Wächter
Institute of Medical Chemistry and Biochemistry, 
#AIDS-Unit at Dermatology Clinic, and *Institute 
of Hygiene, University of Innsbruck, and Ludwig 
Boltzmann Institute of AIDS-Research, Fritz 
Pregl Strasse 3, A-6020 Innsbruck, Austria
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Neopterin: In vitro, large amounts of neopterin 
are released from human macrophages on stimula­
tion with interferon-#. In vivo, neopterin con­
centrations sensitively indicate stimulated cel­
lular immunity, and increased neopterin concen­
trations were observed during rejection episodes 
in allograft recipients, during acute virus 
infections, in autoimmune diseases and in cer­
tain types of cancer. Neopterin concentrations 
correlate to the extent and the activity of the 
disease and bear prognostic information. Besides 
its value as a diagnostic indicator recent 
studies show that neopterin may play a role 
within the cytotoxic repertoir of activated 
macrophages. Neopterin was found to enhance 
radical-mediated effector mechanims such as 
hydrogen peroxide- and chloramine-T-mediated 
cytotoxicity.
Neopterin Measurements: Measurement of neopterin 
is usually performed in serum and/or urine of 
patients. For urine determinations early morning 
urine samples are used, and urinary neopterin 
concentrations are related to creatinine levels.
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Urine measurements are usually performed by 
HPLC. For serum determinations immunoassays are 
commonly used. These tests are also suited for 
measurements of cerebrospinal fluid (CSF). 
Specimens for neopterin measurements must not be 
exposed to direct sunlight irradiation. Repeated 
thawing and freezing of samples has to be 
avoided which is particularly important when 
retrospective analyses are performed.
NEOPTERIN IN HIV INFECTION
Acute HIV infection: During acute HIV infection 
neopterin concentrations in serum and urine rise 
rapidly. Thereafter neopterin levels start to 
decline before antibody seroconversion becomes 
detectable. Similar observations were made also 
during other acute virus infections such as 
cytomegalovirus (CMV) infection. However in 
contrast to CMV, neopterin levels usually do not 
fully normalize in the case of HIV, and approxi­
mately 80% of HIV seropositive individuals con­
tinuously remain with elevated neopterin levels 
even in the asymptomatic phase of infection 
indicating chronic virus production at a low 
level.
Stage of HIV infection: During the course of HIV 
infection neopterin concentrations rise, almost 
all patients with AIDS-related complex or AIDS 
presenting with increased levels. CD4 + T-cell 
counts correlate inversely to neopterin concen­
trations, and significant correlations exist 
between neopterin concentrations in serum and 
urine and the CDC staging system as well as the 
Walter Reed staging classification.
Predictive value: In homosexual men, hemophilia 
patients, intravenous drug users and children 
with HIV infection, neopterin concentrations 
significantly predict progression of the dis­
ease. Patients with higher neopterin concentra­
tions are more likely to progress to AIDS or 
HIV-related death than those with lower levels. 
This is true in early and late stages of HIV 
infection. Further studies show that the predic­
tive value of neopterin is partly independent
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from CD4+ T-cell counts, thus, neopterin values 
are joint predictors of outcome in addition to 
CD4+ T-cell counts. It appears that urine neo­
pterin concentrations are superior to serum 
mesurements.
Zidovudine therapy: Therapy with ziodovudine 
induces significant decline of neopterin concen­
trations in serum and urine. The decline of 
neopterin concentrations in most cases becomes 
significant after approximately 5 days from 
start of therapy and reaches a plateau there­
after. On average the decline of neopterin is 
more long-lasting than the increase of CD4+ T- 
cell counts. Pretherapeutic neopterin concentra­
tions in patients significantly predict outcome 
during treatment with zidovudine.
Cerebrospinal fluid neopterin concentrations:
Intrathecal production of neopterin can be 
demonstrated in patients with HIV infection pre­
ferentially in those with HIV-associated demen­
tia. In addition, neopterin in CSF correlates 
with severity of AIDS-dementia complex. Anti­
retroviral therapy leads to a decline of CSF 
neopterin correlating to improvement of the 
severity of AIDS-dementia complex in patients.
Virus isolation: Patients with HIV infection and 
positive virus isolation in culture have higher 
neopterin concentrations than culture-negative 
patients. Moreover, a correlation exists between 
the replicative capacity of virus isolates and 
neopterin concentrations: higher neopterin 
concentrations are observed preferentially in 
patients whose isolates are classified gualita- 
tively as rapidly growing isolates with high 
replicative capacity (rapid/high according to 
B.Asjö and coworkers). These observations were 
made in individuals with early stages of HIV 
infection.
T-cell proliferative response: Loss of T-cell 
functional response is most expressed in 
progressed HIV infection but it may occur also 
in asymptomatic patients. Particularly in the 
patients with diminished T-cell function some­
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times extremely high neopterin concentrations 
can be observed. Moreover, there exists an 
inverse correlation between loss of T-cell 
responsiveness in vitro and the concentrations 
of neopterin in patients. The data indicate that 
chronic activation of T cells is associated with 
loss of T-cell function.
Drs.Lie and Janeway have shown that interferon- 
plays a critical role in induced cell death 
(apoptosis) . It appears that the status of 
chronic immune activation is inevitably involved 
in apoptosis and induction of tolerance and 
anergy. Pro-oxidants and Ca(2+)-stimuli are 
critical to induce metabolic pathways leading to 
apoptosis. Interestingly, neopterin not only is 
able to enhance radical-mediated effector 
mechanisms, but it also induces influx of Ca(2+) 
into monocytic cells in vitro. Thus neopterin 
may even contribute to apoptosis and T-céll 
anergy in patients with HIV infection.
Neopterin compared to other parameters of immune 
activation: In HIV infection, as in other dis­
eases, neopterin concentrations correlate to 
serum interferon-g levels. Similar strength of 
correlation is observed between neopterin and 
other parameters of immune activation such as 
soluble tumor necrosis factor receptors and ß2- 
microglobulin. However, different behavior of 
parameters can be found in distinct risk groups 
for HIV exposure, e.g., no predictive value of 
ß2-microglobulin appears to exist in IVDUs. This 
observation further supports the view that 
immune activation plays an important role in the 
pathogenesis of HIV infection. In fact, also 
counts of activated CD4+ and CD8+ T-cells 
correlate to neopterin concentrations indicating 
that activated T cells are the source of 
enhanced endogenous interferon-# in patients 
with HIV infection. Similarly, mRNA expression 
of interferon- Ь is enhanced in T cells of 
patients with HIV infection.
HIV pathogenesis: Recently it has been shown
that interferon- , besides other cytokines, is 
able to induce HIV propagation in monocytic cell 
lines. Thus, immune activation may play an
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important role in HIV pathogenesis leading to 
HIV replication in infected individuals. The 
close relationship between neopterin concentra­
tions and the course of HIV infection may 
suggest an even more direct involvement of 
neopterin in HIV pathogenesis. Reactive oxygen 
intermediates and radicals appear to be crucial 
to induce HIV replication via activation of the 
nuclear factor kB (NF-кВ). Such oxygen free- 
radicals are common effector molecules released 
during the oxidative burst of activated macro­
phages. As mentioned above, neopterin is able to 
amplify radical-mediated effects in target 
cells. It is conceivable that neopterin also may 
enhance radical-mediated replication of HIV.
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COMPETITION OF COMPLEMENT PROTEINS AND SPECIFIC 
ANTIBODIES FOR BINDING TO HIV-1 ENVELOPE ANTI­
GENS
G. Füst, Z. Prohászka. T. Hídvégi, N. Thielens1, 
G. Arlaud1, F.D. Tóth2, J. Kiss2, M.P. Dierich3, 
E. Újhelyi
Natl.Inst.Haematol.Blood Transf.Immunol., Buda­
pest, Hungary, 1Inst.Biol.Struct., Grenoble, 
France, 2Inst.Microbiol.Univ.Med.Sch., Debrecen, 
Hungary, 3Inst.Hygiene,,Univ.Innsbruck, Austria
The ability to activate the classical complement 
pathway is an inherent property of the 
transmembrane HIV envelope protein, gp41 (1). 
Previously we have demonstrated that the capac­
ity of gp41 to bind to specific antibody 
markedly decreased after incubation in normal 
human serum. The inhibition was proved to be me­
diated through the classical complement pathway 
activation (2).
The same phenomenon, complement-mediated 
inhibition of gp41-antibody interaction was ob­
served in a reverse system, too: rgp41-coated 
ELISA plates were incubated with mixtures of hu­
man polyclonal anti-gp41 antibody and fresh 
pooled normal human serum (NHS). A marked de­
crease in the amounts of the antibody fixed to 
the plates was observed as compared to mixtures 
containing the same amounts of antibodies in 
buffer. Similar findings were obtained in the 
case of plates coated with synthetic peptides 
corresponding to the immunodominant region of 
gp41. Purified Clq also strongly inhibited anti­
body binding to solid phase gp41 from Clq-anti- 
body mixtures (3).
Due to the inherent complement activating 
capacity of gp41, a well measurable Clq, C4b and 
C3b binding to the rgp41-coated plates occurred 
from NHS with no antibodies. When, however, Clq, 
C4b, and C3b fixation from the antibody-NHS mix­
tures was measured, it was found that at higher 
concentrations, anti-gp41 antibodies signifi­
cantly increased fixation of these proteins to 
rgp41 .
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Similar observations were made by 3 human 
monoclonal antibody preparations. These antibod­
ies - designated as 181-D, 240-D, 246-D - were 
kindly provided by Dr. Susan Zolla-Pazner, Vet­
eran Administration Center, New York). The poly­
clonal antibody preparation was used as control. 
Again different dilutions were prepared from the 
antibodies in buffer and NHS, the antibody-NHS 
mixtures were incubated in ELISA plates coated 
with gp41, and after washing, the amounts of 
fixed antibodies and complement proteins were 
estimated.
An almost complete inhibition of antibody 
binding to the ELISA plates was observed as com­
pared to the buffer control in the case of all 
the four antibody preparations when they were 
added to solid phase gp41 in the presence of NHS 
or purified Clq. No significant differences were 
found between the 3 monoclonals (4).
When complement protein fixation was mea­
sured from the same antibody-NHS mixtures, only 
the monoclonal designated 246-D activated the 
complement since C3 and C4 fixation exceeding 
the control (NHS with no antibody) was observed 
only with that antibody and to a similar extent 
with the polyclonal human antibody. In the case 
of Clq binding, the findings were similar but 
not identical. Slightly more Clq was fixed to 
solid phase gp41 when 181-D and 240-D were pre­
sent in the NHS, as compared to the only NHS 
control. The effect of 246-D (similarly to that 
of polyclonal) was, however, markedly higher.
These results indicate that the complement 
proteins, especially Clq, and the specific anti­
bodies compete for a region corresponding to or 
close to the so-called immumodominant epitope of 
gp41. Previous data (summarized in ref. 1) also 
indicate that the site(s) responsible for com­
plement activation, as well as Clq and C3b fixa­
tion can be localized at that region of the 
transmembrane HIV protein. The mechanism of the 
complement-antibody competetion is summarized as 
a hypothesis (see next page). If the hypothesis 
is correct, the end-result of HIV-complement-an- 
tibody interaction can be formation of HIV-com
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plement complexes which do not contain signifi­
cant amounts of gp41-antibodies (Similar 
experiments with different gpl20 preparations 
are under-way in our laboratories). Interstingly 
enough, Joling et al. (5) demonstrated that 
binding of HIV-1 to follicular dendritic cells 
in vitro is complement-dependent and can occur 
without the contribution of antibodies.
Hypothesis: competition between specific an­
tibodies an complement proteins for gp41
COMPLEMENT PROTEINS AND ANTIBODIES COMPETE FOR 
THE IMMUNODOMINANT EPITOPE OF GP41, THE AFFIN­
ITY OF THE COMPLEMENT PROTEINS IS HIGHER THAN 
THAT OF THE ANTIBODIES
Step la. Gp41 independently of antibodies 
activates the CP which leads to Clq, C4b and 
C3b fixation to gp41
Step lb. The antibody binds to gp41, activates 
CP which leads to Clq, C4b and C3b fixation to
gp41
STEP 1A AND IB MAY TAKE PLACE SIMULTANEOUSLY, 
AND BOTH CAN RESULT IN STEP 2.
Step 2. Binding of complement proteins, mainly 
that of Clq takes gp41-antibody bonds weaker 
and finally can eliminate antibody from the 
transmembrane HIV proteins
END STATE: VIRUS-COMPLEMENT PROTEIN COMPLEXES 
WITHOUT ANTIBODIES?
In the second part of experiments, we ad­
dressed the possible relationship between in 
vitro complement-activation, solid phase gp41-
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antibody-complement interaction and complement- 
dependent enhancement of HIV infection (CDEI) 
using the 3 human monoclonal antibodies men­
tioned above. Antibodies responsible for CDEI 
may play a significant role in the progression 
of HIV disease according to our recent studies 
(6, and Füst et al., AIDS, in press). Little is 
known about the mechanism of complement-depen­
dent enhancement of HIV infection.
CDEI measurements were performed in the 
presence of human complement at two different 
dilutions: at a final dilution of 1 to 40 (used 
in the experiments of Robinson et al. (7), and 
1 to 4 used by our group (6). The results were 
as follows:
1. All the 3 anti-gp41 monoclonals tested 
had marked enhancing effect with both final com­
plement concentrations (1:4 and 1:40). The 
higher the complement concentration was, the 
stronger enhancing effect was observed. Enhance­
ment was manifested not only in the quicker ap­
pearance of HIV-1 RT in the supernatants of HIV 
infected MT-4 cultures but in a significantly 
higher peak levels, too. When we compared the 3 
monoclonal antibodies, no marked differences in 
the CDEI were observed.
2. No correlation was found between the 
ability of the monoclonals to enhance HIV infec­
tion and to increase the complement binding to 
solid phase gp41 (Table). Only the monoclonal 
designated 246-D activated complement, whereas 
marked CDEI effect was found not only with the 
mAb 246-D but with the mAbs 181-D and 240-D as 
well.
These findings indicate that the CDEI ef­
fect cannot be simply explained by an increase 
of complement protein binding to the HIV-viri- 
ons. Other mechanisms, like the interference of 
Clq binding with the gp41-gpl20 bonds may be as­
sumed. Cearly further studies are necessary to 
explain the meechanism of the complement-depen­
dent HIV-infection enhancement.
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COMPARISON OF THE COMPLEMENT ACTIVATING AND COM­
PLEMENT-DEPENDENT HIV-INFECTION ENHANCING EF- 
______ FECTS OF HUMAN ANTI-GP41 ANTIBODIES
Anti-gp41 Inh. of Facilitation of Complement- 
antibody ab.bind- Clq C3b dependent
prep. ing to binding HIV infect.
gp41 by enhancement
NHS/Clq со.dilution
1:4 1:40
181-D ++++ + 0 + ++++
240-D ++++ + 0 +++ +++
246-D 4H—H-f- +++ +++ + +++
p o lyclon. ++++ +++ +++ n.t. n.t.
n.t.: not tested
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EXPOSURE TO HUMAN OR SIMIAN 
IMMUNODEFICIENCY VIRUS WITHOUT 
SEROCONVERSION INDUCES ENVELOPE SPECIFIC T 
CELLS AND ANTIBODIES TO MHC CLASS I ANTIGENS
Alberto B c rc t ta i . Giovanna Rappocciolo1, Stan Weiss2, 
Claudio DeSantis1, Piera Robbioni1, Gene Shearer3, Edward 
C la rc k 4, Anton io  Siccardi1, Raul Benveniste5, Mago C leric i6. 
(1) DIBIT, Ospedale S.Raffacle, Milano, (2) UMD New Jersey 
USA, (3) NCI NIH Bethesda USA, (4) University of 
Washington, Seattle, (5) NCI Frederick M D USA, (6) Cattedra 
di Immunológia. Università di M ilano, Italy.
B a c k g r o u n d : Helper T cell responses to HIV-1 envelope
peptides have been demonstrated in H IV  antibody negative 
individuals who arc at risk for H IV  infection. The absence 
o f  overt signs o f  infection in ind iv idua ls  continuous ly  
exposed to H IV  suggest the poss ib i l i ty  o f p ro tec t ive  
immunity. Protection in animals has been associated with 
the deve lopm ent o f  antibodies that recognize M H C  
antigens. S im ila r  antibodies have also been detected in 
human volunteers vaccinated with candidate HIV envelope 
vaccines. We investigated whether exposure to the virus 
without seroconversion induces both types o f responses. 
Me t ho d s :  Envelope (Env) specific helper T cell responses
(TH), detected as in vitro production o f IL2 by peripheral 
blood T cells, were studied in 36 seronegative intra venuous 
drug users ( IV D U )  and 5 macaques inoculated with various 
dilutions o f  S1V. MHC class I antibodies were detected by a 
competition assay between serum antibodies and a H LA  
class I specific monoclonal antibody.
Resul ts:  Env-spccific  TH responses were delected in 22/34 
(65%) o f  the IV D U  tested and M H C  class 1 antibodies in 
15/34 (44%). 13/34 were positive in both tests and 13/34
were negative in both tests. 3/3 macaques inoculated with 
low dose v irus were positive in both assays and did not 
seroconvert w h ile  2/2 inoculated w ith  high dose v irus 
were negative in both assays and did seroconvert. 
Conc l us i ons :  Env specific TH responses correlated with the
presence o f  antibodies to MHC class I in individuals that 
remained seronegative despite repeated exposure to H IV . 
Infection o f  macaques with low doses o f SIV appeared to 
induce the same types o f  responses in the absence o f  
s e ro c o n v e rs io n .
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COM PLEM ENT AND HIV-1 INFECTION OF HUMAN 
C E L L S
Bover Véronique, and Desgranges Claude
Unité de recherche sur les Hépatites, le SIDA, et les 
rétrovirus humains. INSERM U271. 151, Cours A. Thomas, 
69003 Lyon, France
Objective: To investigate the role of complement in HIV-1 
infection of different types of cells independentely of the 
HIV specific antibodies.
M ethods: To determine the role of complement in HIV-1 
infection we incubated the HTLV-IIIB and HTLV-RF strains 
of HIV-1 with seronegative normal human serum under 
conditions which allow complement activation. The 
incubation of the complement-pretreated viruses was done 
with the human MT2 (CR2+, CD4+), U937 (CR1+ or CR3+, 
CD4 + ) and RAJI (CR2+, CD4') cell lines and with 
peripheral blood T cells. Infection of cells was assessed by 
measuring reverse transcriptase (RT) activity in 
supernatants at different times of culture.
Results: Incubation of different cells with complement and 
virus resulted in enhancement of infection of the cells when 
low amounts of virus were used. For MT2 cells, 
complement activation by viral suspensions occurred 
through the alternative pathway and infection with 
suboptimal amounts of serum-opsonized HIV-1 was 
suppressed by blocking the C3dg receptor (CR2, CD21) on 
MT2 cells with monoclonal anti-CR2 antibody and rabbit 
Fab'2 anti-mouse Ig antibodies. Blocking of the gp120- 
binding site on CD4 under similar experimental conditions 
had no inhibitory effect on infection of MT2 cells with 
opsonized-virus. For U937, RAJI cells and PBL, the 
mechanism of complement activation by HIV-1 will be 
presented as well as for the coculture of PHA-activated and 
HIV-infected PBL from different donors. The role of human 
antibodies against gp41 and gp120 in this complement 
pathway will be presented. The role of homologous 
restriction factors which protected infected cells from 
complement lysis will be discussed.
Conclusion: The complement in the absence of specific 
antibodies enhances infection of C3 receptor bearing cells 
just by the interaction of opsonized virus with the CR1, CR2, 
or CR3 receptors. The clinical relevances of these findings 
remains to be determined.
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CD4 EPITOPE MASKING BY GP120 ON LYMPHOCYTES 
FROM HIV-1 INFECTED PATIENTS DEMONSTRATED BY 
USING A MODIFIED CD4 CAPCELLIA KIT
Carrière D.1, Vendrell J.P.2, Berthier A.M.3, Fontaine C.1,
Reynes J.2, Atoui N.2, Pau B.4
1. Sano fi rec her ch e , Montpellier, 2. Immunologie et Maladies 
Infectieuses, CHU, Montpellier, 3. Centre Médical Rey-Leroux,
La Bouexière, 4. CNRS UMR 9921, Faculté de Pharmacie, 
Montpellier.
We recently reported a two-site elisa  immunoassay (c a p c e lu a  
CD4-CD8, SANOFI DIAGNOSTICS PASTEUR, Clin Chem 1994, 40) to 
measure the concentration of these molecules expressed on the 
surface of peripheral lymphocytes. Given the epitopic specificity 
of the anti-CD4 MAb (domain 1), this kit detects gp120-free CD4 
molecules. Determinations with this assay in HIV-1-infected 
patients treated with AZT have shown a rapid increase of CD4 
concentrations without a concomittant increase in the number of 
CD4+T cells, suggesting unmasking of CD4 molecules. To study 
the masking of CD4 by gp120, we developed a modified 
c a p c e lu a  immunoassay of the CD4 molecules, using an 
antibody directed against a region (domain 2) on the CD4 
molecule independent of the gp120-binding site. Healthy 
subjects taken as controls showed practically identical 
concentrations of the two CD4 epitopes in blood (domain 1 / 
domain 2 > 0.8). The proportion of HIV-1 + patients (n = 66) 
showing significant masking of the CD4 (ratio < 0.8) increased 
with the severity of the disease : 10%, 37% and 80% for 
categories A, В and C, respectively, of the 1993 CDC 
classification. Interestingly, 23% of the patients with CD4+ T- 
lymphocytes counts < 200 pi (n = 40) not only had a gp120-free 
CD4/total CD4 ratio > 0.8 but also presented a good clinical 
status as indicated by a Karnofski's index > 90%. These results 
strongly suggest that the modified c apc elu a  should prove to be 
an important diagnostic tool giving a new approach of the clinical 
status not observed by conventional enumeration.
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LONGITUDINAL ANALYSIS OF THE ANTIBODY RESPONSE 
TO HIV-1 Pi 7 AND P24 IN PATIENTS W ITH HAEMOPHILIA 
D.Chargelegue1, C.Stanley2, C.M.O’Toole1, B.T.Colvin1,
M.W.Steward2
1 LON. HOSP. MED. COL., 2 L.S.H.T.M., LONDON UK.
Objectives. To study the antibody response to H IV  gag proteins 
longitudinally for up to 9 years, specific p 17 and p24 IgG were 
titrated and affinity constants were determined. To assess their 
prognostic value, results were related to CD4 cell counts and clinical 
course o f the patients.
Patients & Methods 16 H IV-1+ patients with haemophilia were 
studied during the period 1984-1993. Following their 1993 clinical 
status patients can be divided into two groups; Asymptomatic: 9 
patients CDCII - AIDS: 5 patients died o f AIDS related diseases and
2 patients are CDCIV. Patients' sera were titrated against 
recombinant (r) H IV-1HXB2 p i?  and p24 in ELISA. IgG affinity 
constants were determined using a double isotope 
radioimmunoassay. Predetermined sera working dilutions were 
incubated with a range o f 10 Antigen (Ag) concentrations containing 
a constant amount o f labelled Ag. Affinity constants (K) were 
calculated: 1/bound Ag = 1/Abt x 1/Kx 1/free Ag + 1/Abt (Abt: total 
antibody binding sites).
Results. All patients who developed AIDS had a continuous decline 
in p i7 and p24 IgG titres from 1986. This decline preceded by 4-5 
years the fall o f CD4 cells to under 200/gl. Over the entire study, 
patients with stable or rising IgG titre remained asymptomatic. The 
IgG affinity values in asymptomatic patients (mean K= 25.5 10^ M" 
1) was higher than in patients who developed AIDS (mean K= 7.16 
10^ IVH). On a longitudinal basis patients who developed AIDS 
lost high affinity antibodies early in the infection; in contrast 
asymptomatic patients maintained high affinity antibodies. 
Conclusions Progressive reductions in IgG titres and affinity were 
earlier predictors o f disease onset than CD4 cell counts by several 
years. Failure to maintain high affinity gag specific IgG , suggests 
that TH cells have impaired function early on. Anti-H IV  antibody 
affinity should be monitored to established whether a protective 
antibody response could be associated with high affinity antibodies.
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ENHANCEMENT ÜF HIV-1 GP41 BINDING TO RAJI CELLS 
BY MITOGENS AND CYTOKINES
Y.H. Chen, S.Opitz, F.Steindl, H.Katinger, M.P. 
Dierich. Ludwig-Boltzmann-Institut für AIDS- 
Forschung and Institut für Hygiene, Innsbruck; 
Institute of Applied Microbiology, Vienna, 
Austria
Based on our finding that HIV-1 gp41 independ­
ently of CD4 can bind to several proteins (gp41 
binding protein) on the human T cell line H9, В 
cell line Raji and monocyte cell line U937, we 
examined the effect of mitogens and cytokines 
on binding of gp41 to H9, Raji and U937 cells. 
Flow cytometry (FACS) analysis demonstrated 
that PWM and LPS, IFN- X and IL-6,but not Con A, 
IFN-OÍ, (3 , cO , and IL-2, could increase gp41 
binding to Raji cells. In controls, none of the 
regulators ( IFN-сУ, ß ,  Y , c*J> , IL-2, IL-6, Con A, 
PWM, LPS) could modify the binding potential of 
H9 and U937 cells. Our data suggest that the 
expression of HIV-1 binding proteins is subject 
to regulation by PWM,LPS,IFN- and IL-6 in case 
of В cells, while on T cells and macrophages 
the binding proteins may be constitutively 
expressed.
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ANALYSIS OF RELATION BETWEEN SYMPTOMATOLOGICAL STATUS 
AND IMMUNOLOGICAL MARKERS ( IL-2R,TNF,CD4s and CD4 
SUBSET ) IN THE COURSE OF HIV INFECTION 
Chiesa A . ,Com o l l i  G . , G a t t i  M.,Campisi D . ,B a r b a r in i  G.
I n s t i t u t e  o f  In fe c t io u s  Diseases-IRCCS Po l .S .Mat teo  
U n i v e r s i t y  o f  Pavia-ITALY
C i r c u l a t i n g  lymphocyte f l o w  cytometry a n a ly s i s  i s  the 
most u s e fu l  and the most a p p l ied  procedure t o  study 
immune m o d i f i c a t io n s  in  t h e  course o f  HIV i n f e c t i o n  
and t o  compare these f i n d i n g s  w i th  o ther  immunological  
markers and symptomatological  s ta tus .
We f o l l o w e d  f o r  e igh t  months 68 HIV p o s i t i v e  p a t ie n ts  
(48 males and 20 females) randomized i n t o  two groups: 
group A) Asymptomatic s u b je c ts  - group B) sub jec ts  
staged i n  IV group (CDC c l a s s i f i c a t i o n , 1987).
In th e s e  p a t ie n ts  we compared some immunological  markers 
( IL-2R so lub le ,TNF,CD4solub le  and CD4 percen tage)  w i th  
symptomato logica l  s ta tu s  and disease s tage.
A f t e r  e i g h t  months o f  f o l l o w - u p  we demonstrated a 
s i g n i f i c a t i v e  d i f f e re n c e  between the groups in  two 
parameters,CD4 so lub le  and CD4 percentage ( p<0.001 ),  
e i t h e r  a t  the beginning , e i t h e r  at the end o f  the study, 
wh i le  t h e  d i f fe re n c e  o f  IL-2R was s i g n i f i c a t i v e  
(p< 0 .001 )  on ly  at the beg inn ing  of  the f o l l o w - u p .  
Never the less  our data d i d n ' t  reveal  any s i g n i f i c a t i v e  
d i f f e r e n c e , i n s i d e  o f  the  same group,between the  beg in ­
ning and the  end o f  our s tudy ,excep t  in  IL-2R le v e ls  
in p a t i e n t s  randomized in  group A.
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CD4 CELL COUNT AND p24 ANTIGENEMIA IN PREDICTING HIV 
DISEASE PROGRESSION: A COMBINED EVALUATION OF 18 
MONTHS FOLLOW-UP.
Comol li  G.,  Chiesa A. ,  Campisi D.,  G a t t i  M.,
Barbar in i  G.
I n s t i t u t e  o f  I n fe c t i o u s  D iseases-IRCCS Po l.S.Mat teo 
U n iv e r s i t y  o f  P a v ia - I t a l y .
Flow cy tometry  i s  w ide ly  used in  the mon ito rsh ip  o f  
HIV i n f e c t i o n  t o  determine CD4 c e l l s  cont ,  considered 
the most s i g n i f i c a t i v e  marker o f  t h i s  i n f e c t i o n .  CD4 
lymphocyte count or percent alone are not,however,  
p rec ise  markers o f  disease p rog ress ion .
Ac t ive  HIV r e p l i c a t i o n  seems t o  be revealed by p24 
ant igen(one o f  core p ro te in s )  d e te c t io n  in the serum 
of  s e r o p o s i t i v e  sub jec ts .  To demonstrated the use - 
fu lness  o f  combined eva lua t ion  o f  CD4 lymphocyte 
c e l l s  and p24 ant igen level  in  p r e d i c t i n g  the HIV 
disease p rog ress ion ,  we s tud ied  these markers in  68 
HIV p o s i t i v e  p a t ie n ts  (48 males and 20 females) 
fo l lowed -up  f o r  18 months HIV disease progress ion 
was s t r i c t l y  r e la te d  to  the CD4 e n t r y  l e v e l ;  
twenty p a t ie n t s  showed de tec tab le  p24 ant igen at  
the beg inn ing  o f  the study. In these pa t ie n ts  we 
observed a more rap id  dec l ine  i n  CD4 c e l l s  count 
compared t o  p24 negat ive ones.
We demonstrated t h a t  the pe rs is tan ce  o f  p24 
ant igen w i th  in c reas ing  l e v e l ,  i s  c o r re la te d  to  
progress ion t o  AIDS and to  a more rap id  decrease 
o f  CD4 lymphocyte popu la t ion ,  l i n k e d  to  a more 
rap id  c l i n i c a l  disease p rog ress ion .
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HUM AN MONOCLONAL ANTIBODIES DIRECTED 
AGAINST THE ENVELOPE OF HIV1 FOR PASSIVE 
IM M U N O T H E R A P Y
C .F ra is ie r ,  K .Crepin, A Afani, V Boyer and 
C.Desaranaes. Unité de recherche sur les Hépatites, le 
SIDA, et les rétrovirus humains, U271 INSERM, 151 cours 
A Thomas, 69003 LYON, FRANCE
O b je c t iv e :  To produce in vitro human monoclonal 
antibodies (HMabs) against the envelope proteins of HIV 
with neutralizing potential for therapeutic applications with 
different methods.
Methods: Epstein Barr virus transformation or fusion with 
murine myeloma of peripheral blood В lymphocytes of 
subjects with neutralizing antibodies or after in vitro primary 
or secondary stimulation of lymphocytes from HIV 
seropositive or seronegative individuals with specific 
envelope peptides.
Screening was done by ELISA on complete virus and with 
synthetic peptides. Neutralization was evaluated for free 
virus on MT4 or H9 cells system, and for passage of virus 
from cell to cell with syncytium inhibition of H9 infected 
cells with SUPT1. The enhancing potential were achieved 
with MT2 and complement and the ADCC analysed on 
U937 infected cells..
R e s u l t s :  15 stable clones producing HIV specific 
antibodies established with the different methods will be 
presented with their principal characteristic features as : 
FACS analysis, peptide identification, neutralizing or 
enhancing potential, complement activation and ADCC. 
The synergetic potential of these HMabs will be discussed. 
Conclusion: Human anti-HIV Mabs can be obtained with 
different methods. These HMabs will help us to further 
characterize the humoral response to HIV infection, define 
biologically significant determinants on HIV proteins, and 
may be useful in clinical applications as passive 
immunotherapy and in a first purpose to prevent the 
infection after an accidental contamination.
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HIV-1 MN-DIRECTED NEUTRALIZING ANTIBODIES AND 
NON INFECTIOUS VIRAL ISOLATES ASSOCIATED WITH 
PROLONGED SURVIVAL IN ASYMPTOMATIC AFRICAN 
CHILDREN WITH PERINATALLY HIV-1 INFECTION 
Fraisier C.1, Van de Perre P.2, Lepage P.2, Desgranges С1 
1 1NSERM U271, Lyon, France; 2National AIDS Control 
Programme Ministery of Health, Kigali, Rwanda
O bjectives  : Analysis of humoral response and HIV-1 
isolates in 11 out of 537 HIV-1 perinatally infected children 
from Rwanda after more than 10 years.
Methods : Neutralizing antibody titers were determined in 
cell-free and in cell-to-cell infection assays with different HIV- 
1 strains. The reactivity of the sera was assessed by ELISA 
against the Principal Neutralizing Domain (PND) of gp120 
from different HIV-1 strains and against V3 consensus 
peptides (US/Europe and Africa). Viruses were isolated from 
PBLs of four children with high neutralizing titers and studied 
for their biological properties.
Results : Nine sera inhibited syncytia formation induced by 
HIV-1 MN-i nfected cells with titers from 40 to 320. Seven and 
nine sera neutralized cell-free virus infection of MT4 cells 
with NIB and the African strain Rll, respectively (titers from 80 
and 640), while ten neutralized MN infection with higher 
titers (80 to 2560). Nine sera showed a strong reactivity 
against the PND from MN but not from HIB, RF and Z2. They 
also reacted against the two consensus V3 peptides. HIV-1 
isolates from PBLs of four long survivors children presented 
a "non-syncytium inducing" or NSI phénotype on SupT1 and 
MT2 target cells. Infection of PBLs with these isolates could 
be also neutralized by their autologous serum. A previous 
study demonstrated in these children a persistent production 
of IgM directed against envelope glycoproteins. The 
biological properties of the specific HIV-IgM of these sera will 
be presented.
Conclusion : The presence in the sera of a neutralizing 
activity against different strains of HIV-1, and of HIV-1 MN V3- 
directed antibodies, as well as the NSI properties of the 
isolates, could also contribute to the prolonged survival of 
these children. Finally, these findings suggest the 
prevalence of a MN-like strain in Rwanda and the 
usefulness of MN-like PND sequences in the development 
of AIDS vaccines in this part of the world.
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LTB4 RELEASE IN CEREBROSPINAL FLUID AS A MARKER 
FOR CEREBRAL CRYPTOCOCCOSIS IN HIV DISEASE
M. Froldi, M. Parma, A. Piona
Istituto di Medicina Interna, Malattie Infettive 
e Immunopatologia, Université di Milano, Milan, 
ItalyINTRODUCTION: Opportunistic infections of
central nervous system (CNS) are frequent in 
AIDS; Cryptococcus meningoencephalitis is one of 
the most common. This latter is characterized by 
unspecific and limited clinical symptoms, since 
usually the signs of meningeal inflammation and 
encephalic involvement are lacking. It often 
occurs late in the course of HIV infection, in a 
phase of severe immunosuppression, but,
sometimes, it may constitute the onset of AIDS 
and it may occur before the appearance of serum 
specific antibodies.
OBJECTIVES: Considering the fact that the
involvement of the immunocompetent cells of CNS, 
during HIV infection, could modify the 
inflammatory response against the infectious 
agent, we evaluated the release of an
inflammatory mediator such as LTB4 in 
cerebrospinal fluid (CSF) of AIDS patients with 
CNS diseases.
METHODS: We studied 12 AIDS patients, mean age
29, with Cryptococcus meningitis, and 12 control 
subjects with inflammatory and degenerative 
pathologies of CNS. LTB4 determination was 
performed by competitive RIA. The diagnosis of 
cryptococcosis was made either by culturel or 
immunoenzimatic tests.
RESULTS: We found very low levels of LTB4 in all 
the HIV-positive subjects (mean 60.5 pg/ml). 
CONCLUSIONS: We deem that can exist a
correlation between the shaded clinical features 
of Cryptococcus infection in HIV patients, and 
the low production of LTB4 by the
immunocompetent cells. The low LTB4 levels could 
depend either on an altered capacity of the 
producing cells or on a reduced response of the 
target cells to the chemotactic stimuli of LTB4; 
both factors lead to a reduction of the
inflammatory reaction in the tissue injury 
following the infection by Cryptococcus.
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An idiotypic network model o f AIDS pathogenesis that is based on 
coselection (mutual positive selection) o f HIV and helper T cells will 
be reviewed 
Geoffrey W Hoffmann
Immune Network Res. Ltd. and Dept.Microbiol.Immunol, and 
DeptPhysics,Univ B C. Vancouver, Canada
I f  H IV mutates to evade the immune response, why can't that 
mechanism be used by any virus or bacterium9 That is, why don't all 
pathogens mutate rapidly to escape the immune system9 An alternative 
AIDS pathogenesis concept is a "coselection" model in which immune 
recognition o f a particular viral strain favours the selection o f that 
strain, which could occur i f  the T cell receptor is involved in the cell 
infection process. Then HIV strains that are recognised by as many T 
cells as possible would be selected. Simultaneously, helper T cells with 
specificity for H IV  would be stimulated and thus selected, which 
would in turn favour the selection o f suppressor T cells with idiotypes 
that resemble (from the point o f view o f Th cell idiotypes). Then 
immunity against H IV  could with time zero in on the "centre-pole" 
idiotypic determinants o f suppressor T cells and contribute to the 
destabilization o f the system seen in AIDS.
The H IV quasi-species and the suppressor T cell idiotypic centre-pole 
would initially not be coincident in shape space, but coselection o f 
helper T cells and H IV  variants together with coselection o f helper T 
cells would make them more and more similar as time goes on. This 
process could account for the variable latency period o f AIDS. 
Inducing immunity to class II MHC (J. Scott, L. Arthur) would perturb 
the network along the anti-MHC—МНС-image axis, and could 
substantially shift the centre-pole. I f  the displacement in shape space is 
large compared with the original distance from H IV to the centre-pole 
this would correspond to an increase in distance in shape space from 
HIV to the centre-pole. This change would lead to a decrease in the 
amount o f complementarity between helper cell idiotypes and HIV, 
which in turn could result in inhibition o f infection. The increase in the 
distance from H IV  to the centre-pole could finally result in a slowing 
down o f the pathogenic process.
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SECRETED PRODUCTS OF H IV -1-SPECIFIC CYTOTOXIC T 
LYMPHOCYTES (CTL) STIMULATE HLA CLASS I AND 
INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1) 
EXPRESSION, AND INCREASE ß2 MICROGLOBULIN LEVELS 
IN  VITRO
Jassoy, Christian1; M. Heinkelein1; H. Klinker2; B. D. Walker3 
institu te  fo r Virology and Immunobiology, department of 
Medicine, University o f Würzburg, 97078 Würzburg, Germany, and 
Massachusetts General Hospital and Harvard Medical School, 
Boston, M A  02114
Objective: We have observed that besides acting directly cytolytic 
H IV -1-specific CTL release a variety of cytokines. To assess further 
the potential role of cytokines released by these CTL we tested the 
ability o f soluble products secreted by HIV-1-specific CTL to induce 
H LA  class I and ICAM -1 expression and to raise ß2 microglobulin 
(ß2M) concentrations in cell culture.
Methods: Supernatants were derived from H IV -1-specific CTL 
incubated with autologous B-lymphoblasts presenting either the 
cognate HIV-1 epitope or a control peptide. A variety o f cell lines and 
peripheral blood mononuclear cells (PBMC) were incubated with 
these supernatants for 24-48 hours. Similarity, cell lines or PBMC 
were cocultured with CTL and their targets. H LA class I and ICAM-1 
expression were determined by flow  cytometry analyses. ß2M 
concentrations in the cell culture supernatants were determined by 
ELISA.
Results: In parallel to lysis o f their cognate target H IV -1-specific 
CTL secrete products that stimulate HLA class I and ICAM-1 
expression on cell lines and on PBMC. As few as 1000 CTL 
significantly induced the expression of these molecules. In addition, 
secreted products of H IV -1-specific CTL enhanced ß2M release by 
PBMC and Jurkat cells. Both effects were mediated primarily by 
IFN-y.
Conclusions: These observations suggest that H IV -1-specific CTL 
may contribute to increased H LA  class I expression in infected tissue 
and elevated ICAM-1 and ß2M concentrations in serum and 
cerebrospinal fluid of infected individuals. In addititon, increased 
H LA  class I and ICAM-1 expression in tissue may facilitate additional 
CD8+ T  lymphocyte responses including immunopathologie activity.
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C O M P A R A TIV E  S TU D Y  ON A N TIB O D IE S  
ASSO CIATED W ITH  D ISEASE PROGRESSION IN H IV  
INFECTION
J. K iss,l C. Süsal,2 E. Ú jh e ly i,3 D. Bánhegyi,4 F.D. Tóth,l 
V. Daniel,2 I. N agy,l G. Opelz,2 G. FüsÚ
1 Inst. M icrob io l., Univ. Med. Sch., Debrecen, Hungary; 2 
Dept. Transplant. Im m unol., Inst. Im m unol., Univ. 
Heidelberg, Germany; 3 Natl. Inst. Haematol., Blood 
Transfusion and Immunol., Budapest, Hungary; 4 St. László 
Hospital, Budapest, Hungary
Complement-dependent enhancing antibodies and anti-Fab 
antibodies were measured in parallel in serum samples o f 7 
longitudinally tested H IV -in fected patients and in sera o f 15 
patients w ith advanced A ID S . H IV -in fection  enhancing 
antibodies were determined using a CR2-carrying cell line. 
IgG and IgA class autoantibodies directed against human IgG- 
Fab fragments were measured in ELISA assays. Significant 
negative correlations were found between C D4+ cell counts 
and IgG-anti-Fab and IgA-anti-Fab antibodies. A  significant 
positive correlation was observed between complement- 
dependent enhancing antibodies and IgA-anti-Fab antibodies. 
Our findings indicate that enhancing antibodies and 
autoantibodies directed against IgG-Fab are not identical.
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MUCIN-LIKE SUBSTANCE TRAPING FREE ELECTRONS IN 
SERA OF HIV-INFECTED PATIENTS SHOWS AFFINITY TO 
HIV-1 ENVELOPE AND SHARES IN HIV-MEDIATED 
IMMUNOSUPPRESSION
Kulberg, A.J., Babaeva, E.E., Tarkhanova, I.A., 
Cheknev, S.B.
N.F. Gameleya Epidemiology and Microbiology 
Institute, 123098 Moscow, Russia
Mucin-like domains (MLD) of human peripheral 
mononuclear adhesins are regularly observed in 
sera of HIV-infected patients while their level 
is higher in the patients with KS. MLD show the 
property of traping free electrons followed by 
their passage to the hydoxyl group of water with 
the hydroxyl anion radical formation. MLD are 
also capable of binding to the HIV envelope 
recombinant protein and apparently affect 
thereby the HIV-l-mediated infectivity of the 
MT4 established cell line. According to data 
obtained in vitro and in vivo MLD demonstrate 
the immunosuppressive activity interfering, in 
particular, with the phytomitogen-induced 
activation of normal human peripheral 
mononuclears and with inhibiting the NK cell 
antitumor cytotoxicity. All these findings may 
indicate that MLD are probably involved to the 
progression of HIV infection.
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MOTHER TO CHILD TRANSMISSION OF HUMAN 
IMMUNODEFICIENCY VIRUS TYPE 1: ROLE OF MATERNAL  
ANTIBODIES MEDIATING CELLULAR CYTOTOXICITY AND 
VIRAL NEUTRALIZATION
Aloise MabondzoO), Gabriel Gras<1>. Jacques Rostockén1), Véronique 
Beyssenn), Dominique Marcéi’), François Hervé!2), Françoise Parnet- 
Mathieu<3). Christian CourpotinW and Dominique Dormontb)
(1). Lab de Neuropathologie expérimentale et Neurovirologie, CRSSA/CEA. 
Fontanay-aux-Roses, France (2) CHU Saint Antoine, Paris, France (3) Centre 
d’Hématologie Périnatale, Paris, France (4) Hôpital Trousseau, Paris, France
Mother to child transmission is an important mode of 
spread for human immunodeficiency virus type 1 (HIV-1). This 
leads to a significant proportion of infected babies born to HIV-1 
infected mothers. Several evidences exist to support in utero 
HIV-1 transmission processes. However the mechanism of the 
transmission of the virus to the newborn is not well Known. In 
this view, a retrospective study of sera from mothers infected 
with HIV-1 was undertaken to investigate whether humoral 
response in infected mothers correlates with vertical 
transmission of the virus. Therefore, sera from infected mothers 
(transmitters) who had given birth to infected children and from 
infected mothers who delivered uninfected children (non 
transmitters), were analyzed for the presence of antibodies that 
mediate antibody dependent cellular cytotoxixity (ADCC) and 
virus neutralization. Titer distributions in transmitter (T) and non 
transmitter (NT) groups were then compared. We showed that 
ADCC titers serum dilution giving 10% specific lysis, T= 10; 
NT=12) and neutralizing titers in human monocyte-derived 
macrophages (MDM) (T=15; NT=20) were not linked to virus 
transmission (P=0,73 and P=0,88 respectively). However, 
neutralization titers in MT-2 cell line were significantly higher in 
NT mothers (n=21) than in T mothers (n=14). The discrepancy 
between neutralization titers in MT-2 cells and in MDM leads us 
to increased cohort size to more precisely investigate the 
involvement of humoral factors in protection against HIV-1 
vertical transmission.
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A S t u d y  of th e  D is a p p e a r in g  IL -2 r R e c e p t o r s  (C D 25) 
F r o m  L y m p h o c y te s  D u r in g  S im u lt a n e o u s  M u l t i-c o lo r
IMMUNOPHENOTYPING
Ferenc F. Mándy, Michèle Bergeron, and Dragica 
Bogdonovich
Bureau of HIV/AIDS Laboratories and Research 
Laboratory Cenre for Disease Control, Health Canada, 
Ottawa, ON, Canada
Induction of IL-2 synthesis and expression of the 
heteromeric IL-2 receptor (R) complex are key events in T- 
cell activation. CD25 molecule has been recognized as a 
cellular activation marker with possible association related to 
determination of slow or fast progressing form of the HIV 
disease. With the recent renewed interest in depeptidyl IV 
(CD26) molecules in conjunction with HIV-1 infection of CD4 
T-cells, the understanding of the IL-2R’s contribution is 
essential. It is generally accepted that simultaneous multi­
color immunophenotyping is the appropriate tool to develop 
to study activation status of leukocytes. It is hoped that with 
multi-fluorescence labels, immunophenotyping will provide 
some insight into the biology of cellular activation events 
during early stages of HIV infection. For the better 
understanding of the biology of cellular activation markers 
such as CD25 and CD38, simultaneous three and four color 
immunophenotyping protocols are replacing the traditional 
single and dual-color approach which are currently still 
utilized in clinical flow cytometry.
In this evaluation of simultaneous three and four-color 
protocols with CD45FITC, CD4ECD, CD3PerCP, and 
CD25PE, some sever restrictions have been observed. 
When the monoclonal antibodies are premixed, the 
percentage of CD25 positive cell are reduced from an initial 
32% to: 19-31%, 15-24%, and 13%, correspondingly with 
simultaneous two, three and four-color combinations 
respectively. These significant losses of surface expression 
are only partially due to the complex color compensation 
matrices.
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THE ROLE OF VIRAL PROTEASE (PR) IN THE EARLY PHASE 
OF HIV-1 REPLICATION PREVENTION OF PRIMARY HIV-1 
INFECTION BY INHIBITORS OF PR
Nagy K.1, Young M.2 Merson J 3, Whittle P 3, Oroszlán S 2
1National Institute for Dermato-Venereology, Budapest, 2 LMV, 
ABL-BRP, NCI-FCRD, Frederick, MD 21702, 3 Pfizer Central 
Research, Sandwich, Kent, United Kingdom
HIV replication and expression is under the control of viral 
regulatory proteins and the endogenous cytokine network 
Recently it was reported (Riviere et al.,Nature 350:625, 1991), that 
in HIV infected cells - similarly to cytokines - the activation of 
cellular transcription factor NF-кВ is also specifically induced 
during the course of infection, which may be regulated by viral 
gene product: the HIV-1 proteinase, resulting the replication of 
HIV Here we provide evidence for prevention of primary HIV-1 
infection in vitro by inhibitors of viral PR, and for its role in the early 
phase of viral replication. The antiviral activity of substrate-based 
inhibitors of HIV PR, UK-88,947 and UK-112,812 was quantitatively 
determined in a single cycle of infection using the MAGI infectivity 
assay (Kimpton and Emerman, J Virol 66 2232, 1992) Both 
compounds inhibited primary infection by HIV-1 >|R and the 
replication-defective HIV-gpt(HXB-2). ICM values were in the range 
of 12-15 pM and 3-4 pM respestively. The progression of HIV 
cDNA synthesis in the cells treated with PR inhibitor was analyzed 
by PCR at 4 h and 18 h post infection using four primer sets 
recognizing various regions of the viral genome. At 4 h cDNA was 
detected with all primer pairs but after 18 h the g ag  and the 
LTR/gag specific primers were unable to amplify cDNA We 
conclude that PR inhibitors do not affect virus entry or initiation of 
reverse transcription and that the cDNA transcribed in inhibitor- 
treated cells is not integration competent, stable cDNA It is likely 
that the target of the PR in the early phase of viral replication is the 
nucleocapsid (NC) protein and its cleavage may be necessary for 
the formation of a properly assembled cDNA-protein complex, the 
prentegration complex and/or its transport to the nucleus. These 
and other results suggest that PR and NC protein itself and/or its 
proteolytic fragments may have an active role in the early phase of 
virus replication.
(Supported by NCI, DHHS .under contract N01-CO-74101 with 
ABL).
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TR AN SC ELLU LA R  TR AN SAC TIVATIO N  OF H IV -1 BY HHV-6
Ongràdi, J.12, 'R. luliano, 4YI. Rossi and ' L. Ceccherini-Nelli 
lDept. Biomedicine, section o f Virology, Univ. Pisa, Pisa, Italy 
2Institute o f Microbiology, SOTE, Budapest, Hungary, on leave
In vivo transactivation o f H IV-1 by HHV-6 has been postulated 
on the bases o f in vitro experiments and believed to be important in 
the acceleration of AIDS progression. We detected HHV-6 active 
replication more frequently in IVDA (107/135, 79%), than in 
hemophiliacs (11/35, 31% , p< 0.001) and in blood donors (26/145, 
18% p<0.001). 81% (110/135) o f IVD A was positive by HIV-1 
DNA PCR and, in spite o f specific retroviral therapy, expressed 
H IV -1 in 54%; 43% (58/135) of these also expressed HHV-6 
sequences evidently able to transactivate H IV-1, since they effected 
in a two years' period, both CD4 count and mortality.
To determin i f  the disregulation of humoral factors present in 
H IV-1 infected patients could be due to humoral factors released 
form H H V-6 infected cells, we infected HSB-2 w ith HHV-6 and/or 
treate them with LPS. Surnatants were also mixed to CEM-ss cells 
infected w ith a range o f H IV - l  inocula to quantitate syncytia, RT 
and p24 antigen production in time. A t d ifferent time intervals 
aliquots o f filtered, HHV-6-free supernatants, were also analyzed for 
cytokines and ,5-S-Met labelled proteins.
H H V-6 cvtopaticity in unfiltered supernatants increased from day 
10 to 15 p.i. TNF-release post HHV-6 infection was biphasical, on 
day 1 and 4, suppressed on day 2; it peaked at 12 h with LPS 
treatment. HHV-6 infection resulted in no IF N  release; its 
production induced by LPS was restricted between day 1 and 4.
V irus free supernatants o f HHV-6 infected cultures obtained 
between 24 to 48 h p. i. increased HIV-1 production up to 30-fold, 
but no discrete protein band was evident in standard polyacrilamide 
gels to be released concomitantly. Mediators released late during 
fu ll blown HHV-6 infection decreased HIV-1 production. HIV-1 
activation by HHV-6 was decreased by simultaneous LPS treatment. 
Supernatants from LPS treated uninfected cultures increased HIV-1 
production moderately. These data suggest two possible ways o f 
transactivation of H IV  by HHV-6: a moderate and continuous one 
by TN F  and a very efficient, but transient one by an unidentified 
early diffusible product o f HHV-6 infected cells. □
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SERUM SCD23 AND IgE LEVELS IN HIV-1 INFECTION: 
WHAT CORRELATION ?
A .Perrella, S .Guerriero,E .Soscia, L.Finelli,and
0.Perrella
III Department of Infectious Diseases Hospital 
D.Cotugno, Naples,Italy
OBJECTIVE The aim of the present study was to 
determine the possible correlation between 
sCD23 and IgE levels in HIV-infected patients.
METHODS We have selected 18 HIV-positive pati­
ents, who presented the following symptoms: chr­onic pruritic dermatitis,hypereosinophi1ia and 
high IgE levels.The blood donors,HIV-negative, 
as a control group,were recruited.In all patie­nts we have examined in duplicate solubleCD23 
molecule levels by ELISA test (T Cell Diagnos­
tics , CA , MA , USA ). The sensitivity of this test was : 15 U/ml.
RESULTS SCD23 levels in 16 HIV-infected patie­
nts ranged from 200 to 840 U/ml,and a signifi­
cant correlation (r=.764; pc.001) was found be­
tween sCD23 and IgE levels in their serum. In 
these patients CD4+ cells were extremely redu­ced (median 60 cells/mmc).
CONCLUSION Our limited results suggest that in
HIV infection it is possible a correlation be­tween sCD23 molecules and IgE levels and the da­
ta support the hypothesis that this hyper IgE 
could be at least in part induced by sCD23 mo­
lecules. It is possible that the elevated pre­
sence of CD23 expression on T cells,in spite of 
their paucity, may lead the second signal for 
the production of IgE in vivo.
(Supported by grants of Project AIDS,n08202-03)
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COMPLEMENT ACTIVATION BY RECOMBINANT HIV 
ENVELOPE PROTEINS: COMPARISON BETWEEN GP41 AND
GP12°  , .
Z Prohászka, T. Hídvégi, E. Újhelyi, H. Stoiber1, MP. Dierich1, C.
Susal- and G Füst
Natl. Inst. Haem., Blood Transf. Immunol., Budapest, Hungary, Hnst 
Hygiene, Univ. Innsbruck, Austria, 2Inst. Immunol., Univ. Heidelberg, 
FRG
The human immunodeficiency virus type 1 possesses the ability to activate 
the human complement system. The aim o f our study was to investigate 
which envelope glycoprotein(s) do activate the human complement system 
and via which pathway. We used a self-made solid phase ELISA system. 
Plates were coated with recombinant, non-glycosylated gp41 (N-terminal 
185 amino acids) or with different recombinant gpl20 preparations with or 
without glycosylation. Plates were then incubated with fresh, pooled 
human serum (NHS) or with heat inactivated (56°C, 30 min.) human 
serum (HNHS) as a control. Fixed complement proteins were detected 
with specific, peroxidase labeled antibodies against different complement 
proteins (C lq , C3, C4). For colorimetric measurements we used OPD, 
optical density was measured at 492 nm.
We found that both gp41 and gpI20 do trigger the complement cascade 
but in different manner. While gp41 bound C lq, C4 and C3 components, 
in the case o f non-glycolysated gpl20 we found only C3 to fix to the plate. 
The results indicate that the complement activation by gp41 take place 
through the classical pathway, whereas gpl20 triggers the alternative 
pathway.
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Evidence for structural and functional homology between human C1q 
and gp120 of HIV-I
H. Stoiber’ 2, N. Thielens3, C. EbenbichleryG. Arlaud3, M.P. Dierich12
’Ludwig Boltzmann Institut für Aids-Forschung, Innsbruck, Austria; 
Institut für Hygiene, Innsbruck, Austria; 3lnst. Biol. Structurale, Grenoble, 
France
Institut für Hygiene, Fritz Preglstr 3, 6020 Innsbruck
Earlier we provided evidence for an interaction between C1q, 
subcomponent of the first complement component C1, and the outer' 
membrane part of gp41, the TM protein of HIV-I (Ebenbichler et al. J. 
Exp. Med. 1991). On the other hand it is well established, that gp41 
interacts with gp120, the SU protein of HIV-I. We therefore asked the 
question, whether structural and functional homologies exist between 
C1q and gp120. First, in addition to the earlier described C1q binding 
site, we identified one further C1q binding region in the N-terminal fusion 
part of gp41 (peptide P526: aa 526-538). Second, we studied the effect of 
gp120 on the gp41/C1q interaction. Preincubation of recombinant soluble 
gp41 (rsgp41; aa 539-684) or P526 with gp120 abolished binding of 
C1q; gp120 and C1q competed for binding sites in rsgp41 and P526. 
Third, a polyclonal antiserum to gp120 recognized C1q and an antiserum 
to C1q recognized gp120 in both ELISA and agglutination assay. These 
data suggest competition of gp120 and C1q for the same sites in gp41, 
antigenetic homology between gp120 and C1q, and raise the possibility 
of an autoimmune phenomenon on the basis of molecular mimicry.
Supported by Ludwig Boltzmann Gesellschaft, State of Tyrol and the 
FWF Austria
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IgA-ANTI -FAB AUTOANTIBODIES AND DISEASE 
PROGRESSION IN AIDS
IC. Süsal, IV. Daniel, 2F.D. Toth, 3E. Újhelyi, 
3G. Füst, and IG. Opelz. llnst. of Immunol., Univ. 
of H e i d e l b e r g ,  Germany; 2Inst. of M i c r o b i o l . ,  Univ. of 
D e b r e c e n ,  Hungary; 3Natl. Inst. of Haematol., Blood 
Transf. a n d  Immunol., Budapest, Hungary
We showed recently that IgA antibodies directed 
against the Fab portion of the IgG molecule are 
strikingly associated with disease stage in 
patients with head and neck cancer, who commonly 
have immune defects. Furthermore, we 
demonstrated that kidney graft recipients with a 
high pretransplant IgA-anti-Fab autoantibody 
activity had a significantly better graft 
survival rate than patients with a low 
pretransplant IgA-a-Fab, underlining the immuno­
suppressive property of these antibodies. In 
this study we investigated whether IgA-a-Fab 
antibodies occur during HIV infection and are 
associated with disease progression. 130 sera of 
33 HIV+ hemophiliacs with AIDS/ARC, 178 sera of 
73 asymptomatic HIV+ patients, 47 sera of 38 
HIV- hemophiliacs, and sera of 72 healthy 
controls were tested in an ELISA. AIDS patients 
had significantly higher IgA-a-Fab than ARC 
patients, asymptomatic HIV+ patients, HIV- 
hemophiliacs, or healthy controls (p<0.02, 
0.0001, 0.001, and <0.0001, respectively). An
inverse association was found between IgA-a-Fab 
and CD4 counts (r=-0.4, p<10-6) , and this was
confirmed in sequential follow up studies. 
Moreover, IgA-a-Fab was associated with serum 
neopterin (r=0.3, p<10-5) and, in a separate
study, with complement-dependent enhancing 
antibodies (r=0.4, p<0.005). Sera with high
titers of complement-dep. enhancing antibodies 
had a 3 times higher IgA-a-Fab than sera with 
low titers (p<0.005 ) . Affinity purified a-Fab 
bound to rgpl20-coated, uninfected CD4+ T cells. 
A-Fab antibodies appear in different diseases in 
association with a suppressed immune status and 
seem to reflect a disturbed immune network. A- 
Fab may contribute to the elimination of CD4+ T 
cells by crosslinking the CD4 molecule via gpl20 
or gpl20/a-gpl20 attachment with the TcR.
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TWO COUNTERACTING GROUPS OF AUTOANTIBODIES IN 
AIDS
IC. Süsal, 2G. W. Hoffmann, IV. Daniel, 2M. D. 
Grant, and 1G. Opelz
llnstitute of Immunology, University of 
Heidelberg, Germany; 2Immune Network Research 
Ltd., Vancouver, Canada
We reported recently on an association of anti- 
Fab autoantibodies with disease progression and 
loss of CD4+ T cells in HIV+ hemophilia patients 
(Blood 1992; 79:954). We now tested sera of the 
same HIV+ patients and controls for 
antiidiotypic activity against anti-gpl20, anti- 
CD8, anti-CD4 monoclonal abs, subclass controls, 
and rCD4. A significant association was found 
between a-a-gpl20 and a-a-CD8 or a-rCD4 
activities (both: r>0.7, p<10-°). Follow up 
studies confirmed that these activities 
decreased and increased in parallel during 
disease development. Importantly, an opposite 
behaviour was observed between these three 
activities and a-Fab autoantibodies. The highest 
a-rCD4 activity was found in HIV+ patients with 
301-800 CD4 counts, whereas these patients had a 
low a-Fab activity. In patients with 301-800 CD4 
counts the a-Fab/a-rCD4 ratio was 2.5±0.4, 
significantly lower than in patients with <50 
CD4 counts (7±2.6, p<10-4). Affinity purified a- 
rCD4 antibodies contained a-a-gpl20 activity 
which could be inhibited with rCD4. Affinity 
purified a-gpl20 antibodies contained a-Fab 
activity and bound to MHC class II molecules. It 
is known that Fab binds rCD4, CD8 binds MHC I, 
and CD4 binds MHC II and gpl20. Based on these 
interactions, the existence of two biologically 
distinct groups of molecules with similarities 
to MHC I (a-Fab, a-CD8, CD4) or MHC II (gpl20, 
Fab, a-a-gpl20, a-a-CD8, a-rCD4, CD8) can be 
hypothesized. Disturbance of the equilibrium 
between group I (deleterious?) and group II 
(protective?) autoantibodies appears to play a 
role in the immunopathogenesis of AIDS.
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COMPLEMENT ACTIVATION BY GP12O-COATED UNINFECTED 
CD4+ T CELLS
C. Süsal, M. Kirschfink, M. Kröpelin, V. Daniel, 
and G. Opelz
Institute of Immunology, University of 
Heidelberg, Heidelberg, Germany
The mechanism of CD4+ cell depletion in HIV 
infected patients is poorly understood. In the 
present study we investigated whether gpl20- 
coated uninfected CD4+ T cells of healthy 
individuals can activate complement in the 
absence of anti-gpl20 antibodies.
In f lowcytometry analysis, we found that the 
complement proteins C4, C3d, C5, C5b-9 and
properdin bind to rgpl20-precoated normal CD4+ T 
cells of healthy individuals when incubated in 
autologous serum. Complement activation occurred 
primarily via the classical pathway; in the 
presence of EDTA, Mg-EGTA or C4-deficient human 
serum, no complement proteins were bound to 
rgpl20-coated CD4+ cells. rgpl20 which was 
immobilized on the surface of microtiter plates 
activated complement in the absence of 
lymphocytes. In a lymphocytotoxicity assay, 
addition of rabbit sera from different sources 
or a mouse serum to rgpl20-preincubated CD4+ T 
cells resulted in total lysis of CD4+ T cells, 
which was abolished by heat inactivation or in 
the presence of EDTA or Mg-EGTA. No lysis was 
observed with autologous or homologous normal 
human serum.
Our data indicate that attachment of free 
circulating gpl20 molecules to uninfected CD4+ T 
cells can activate complement in the absence of 
anti-gpl20. Although not resulting in direct 
cell lysis, complement activation with sub- 
seguent opsonization may represent a mechanism 
for the elimination of uninfected CD4+ T cells 
by the reticuloendothelial system.
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INTERACTION BETWEEN THE Cl COMPLEX OF HUMAN 
COMPLEMENT AND HIV-1 INVOLVES THE Clq 
GLOBULAR HEADS AND A MAJOR SITE ON THE 
TRANSMEMBRANE ENVELOPE GLYCOPROTEIN gp4I
N.M . Thielens1, I.M . Bally1, C.F. Ebenbichler2, M .P. Dierich2 & 
G.J. Arlaud1
'Institut de Biologie Structurale/LEM, Grenoble, France, and 
2Institut für Hygiene and Ludwig-Boltzmann Institut für AIDS- 
Forschung, Innsbruck, Austria
Previous studies have provided evidence for activation of the 
human C l complex by HIV-1, resulting from direct interaction 
between C lq  and the external portion o f the viral transmembrane 
envelope protein, rsgp41. The present study was undertaken to 
locate more precisely, within C lq  and rsgp41, the sites involved in 
the C l/H IV -1 interaction. Using a solid-phase binding assay, we 
showed that 125I-labeled C lq  binding to rsgp41 was dose- 
dependent, saturable, and comparable to binding o f C lq  to IgG- 
ovalbumin immune complexes. The globular (GR) and , to a lesser 
extent, the collagen-like (CLR) regions o f C lq  both bound to 
rsgp41. In contrast, the GR inhibited the Clq/rsgp41 interaction, 
whereas the CLR did not. A series o f peptides covering the 
putative C lq  binding site on gp41 (positions 590-613 o f gp 160) 
were synthesized and used as competitors in the Clq-rsgp41 
binding assay. Peptide 601-613 (GIWGCSGKLICTT) inhibited 
C lq  binding the most efficiently, with 50% inhibition at a 
concentration o f 100 ^M . This peptide also inhibited binding of 
C lq  to rsgp36, the protein o f HIV-2 homologous to rsgp41. The 
inhibitory effect o f this peptide was dependent in part on the 
presence o f the S-S bridge normally connecting Cys 605 to Cys 
611, as reduction o f this bond significantly reduced its efficiency. 
These data suggest that the C lq /H IV -1 interaction involves a site 
on C lq  located within the globular regions, and a major site 
located within the immunodominant domain o f H IV -1, which 
shares homology with the corresponding region o f H IV-2.
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ALTERED PRODUCTION OF CYTOKINES MODULATING 
HEMOPOIESIS BY CIRCULATING CELLS OF SUBJECTS WITH 
HIY INFECTION
T im itilli S, Balleari E, Bason C, Puppo F, Ghio R.
Department o f Internal Medicine - University o f Genoa - Italy
Introduction: We recently observed a direct, inhibitory activity on in 
vitro hemopoiesis by autologous T lymphocytes from H IV  +  
subjects. Actually, supernatants from in vitro coltures o f T 
lymphocytes of HIV +  individuals demonstrated a decreased 
stimulating activity and an increased inhibitory activity on in vitro 
growth o f hemopoietic progenitor cells. In order to better define 
which soluble factor(s) might be involved in such biological activity, 
we studied the production o f  cytokines with known effect on 
hemopoiesis from circulating mononuclear cells o f H IV +  
individuals.
Methods: Short-term (72h) in v itro  coltures o f T lymphocytes were 
established using standard methods with and without mitogen (PHA) 
from 9 H IV  individuals (6 males - 3 females, age range 21-28 years) 
and 7 age- and sex-matched healthy volunteers (used as controls). 
Concentrations of IL-3, IL -6 , GM-CSF, TNF-a, TNF-ß and TNF-y 
were evaluated in supernatants (SN) using specific commercially 
available immuno-assays.
Results: In the absence o f mitogen, concentrations (pg/ml) o f both 
T N F -a  and TNF-ß in SN (mean ± SD) were found to be 
significantly higher in H IV  +  subjects than in normal controls (324± 
168 vs 62,8±56,9, p <  0,001 and 210±271 vs 12,5± 10,7, p <  
0,001, respectively). In SN from coltures o f PHA-stimulated T 
lymphocytes GM-CSF concentrations (pg/ml) were lower in H IV  +  
subjects when compared to normal controls (6419.9±6522 vs 15584± 
2783.4, p <  0,05)
Conclusions: Our date indicate that T lymphocytes from H IV +  
subjects spontaneously produce increased amounts o f cytokines with 
inhib itory effects on hemopoiesis such TNF-a and TNF-ß, while, 
where stimulated, shown a decreased production o f GM-CSF. These 
data suggest that an abnormal production o f cytokines modulating 
the hemopoiesis by autologous lymphocytes might cooperate to the 
defective hemopoiesis associated with HIV infection.
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A N T IB O D Y -D E P E N D E N T  E N H A N C E M E N T OF HIV-1 
IN FE C TIO N  IN  H U M A N  TERM SYN C YTIO - 
TR O PH O BLAST CELLS C U LTU R ED  IN V IT R O
F. D. Tóth, 1’2 p Mosborg-Petersen,! J. Kiss,2 G. Aboagye- 
Mathiesen,! M. ZdravkovicJ H. Hager J J. A ranyosi,^  L. 
Lampé,3 and P. Ebbesen^
1 The Danish Cancer Society, Department o f  Virus and 
Cancer, Aarhus, Denmark, 2 Institute o f M icrob io logy and 2 
Department o f Obstetrics and Gynaecology, University 
Medical School, Debrecen, Hungary
We examined i f  Fc receptor-mediated antibody-dependent 
enhancement (FcR-ADE) o f complement-mediated antibody- 
dependent enhancement (C '-A D E ) o f virus infection can 
contribute to increasing replication o f H IV-1 in human 
syncytiotrophoblast (ST) cells. We found that both FcR-ADE 
and C '-A D E  may result in enhanced virus release from H IV - 
1-infected ST cells. We showed that FcR -AD E o f HIV-1 
infection is mediated by FcR III and other FcR(-s) belonging 
to undetermined Fc classes and does not require CD4 
receptor, whereas C '-AD E uses both CD4 and CR2-like 
receptors. FcR-ADE seems to be more e ffic ient in enhancing 
HIV-1 replication than C '-ADE. W hile FcR -AD E leads to 
increased internalization o f  H IV -1, C '-ADE does not result in 
enhanced endocytosis o f  the virus. In addition, antibodies 
mediating FcR-ADE are reactive w ith the g p l2 0  viral 
envelope antigen, whereas antibodies involved in C '-ADE 
react w ith  the viral transmembrane glycoprotein gp41. Our 
data suggest that both FcR-ADE and C '-ADE may contribute 
to the spread o f H IV -1 from mother to the fetus.
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A human monoclonal antibody against HIV-1 gp l20 capable o f broad 
neutralisation, complement activation and ADCC 
A Trkola, M  Purtscher, A Buchacher, G Gruber, T Muster and H 
Katinger
Institute o f  Applied Microbiology, University o f Agriculture, Vienna, 
Austria
Previously we established a panel o f human monoclonal antibodies 
against H IV-1. Out o f these we identified the anti-gpl20 humAb 2G12 
showing broadly neutralising and syncytia inhibiting activity against 
divergent isolates o f HIV-1. This inhibiting activity o f HumAb 2G12 
was found with laboratory strains o f H IV -1 (IIIB , RJF, SF2) as well with 
a panel o f  primary isolates o f  SI and NSI phenotype. No syncytia 
inhibition was observed when the MN strain was used as virus inoculum 
although 2G12 binds to M N infected cells. Testing the influence o f 
active human complement in syncytia inhibition assays we observed that 
2G12 also effectively inhibits syncytia formation w ith MN when active 
complement was added to the assay. Additional experiments revealed 
that 2G12 mediates a remarkable deposition o f C3 to MN- and RF- 
infected CEM,NKR cells. 2G12 was also found to be a potent mediator 
o f ADCC against cells infected with HIV-1 strains IIIB , MN and RF. 
We assume that 2G12 due to its outstanding properties is an interesting 
candidate for passive immunotherapy in AIDS.
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INHIBITION OF NORMAL NATURAL KILLER AC TIV ITY BY 
SERA FROM H IV +  HAEMOPHILIC PATIENTS: ACTION OF IL-2 
Vulcano, M, Galassi, N, Felippo, M, Vernava, D, Olabuenaga, S 
IIHEMA. Academia Nációnál de Medicina, Buenos Aires, Argentina
Deficient natural killer (NK) cell activity has been observed in 
haemophilic patients (He), with positive serology for the human immune 
deficiency virus (H IV). We previously demonstrated the inhibitory effect 
on normal NK activity by H IV + sera from He, which increased as the 
infection progressed.
Sera were obtained from H IV+ He n=20 classified according to the CDC 
(groups III, IV A , IVC2 and AIDS), and normal controls (N) n=18. The 
cytotoxic assay was done using normal peripheral blood mononuclear 
cells (PBMC) as effector cells and ^'C r-K562 as target cells during 4 h 
at 37 ° C . Cells were treated or not with interleukin 2 (IL-2) ( 18 h) before 
or after 4 h incubation with sera or simultaneously during 18 h.
NK function was significantly inhibited by H IV + sera both under 4 or 18 
h incubation in comparison to N. Inhibition % x±S.E.: a) H IV + 4 h: 
22.3±3.2; b) H IV + 18 h: 41 7±6.6; c) N 4 h. 4 .2 ± l. l ;d )N  18 h: 7.1±2.6. 
The results o f IL-2 treated cells were the following: inhibition % x±S.E.: 
e) IL-2, H IV+ : 23.U3.3; 0 H IV +v IL-2: 12.6±3.2;g) H IV+ + IL-2: 
26.6±7.4. (a vs. e: p=0.76, vs. f: p=0.007; b vs. g: p=0.015). The 
inhibitory effect o f sera was similar in all the groups o f patients studied. 
Treatment o f the PBMC with sera from N controls did not modify the 
NK activity in any experimental group.
These results indicate that IL-2 activation o f normal NK activity does not 
change the inhibitory effect by sera, but i f  IL-2 activation occurs at the 
same time or after sera treatment, a partial restoration on NK function is 
observed. Serum factors present in H IV + sera can aggravate the 
functional defect o f NK cells in H IV  infection, thus is important that a 
lymphokine like IL-2 could partially revert this effect.
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A SEVEN YEAR STUDY OF 200 HIV+ve DRUG USERS
Whitelaw James, Greenwood E, Burrells N.
H IV  Immunology Unit,Royal Infirmary,Edinbugh
Introduction
This cohort o f HIV-infected intravenous drug users 
all seroconverted during 1983-4. The trend in CD4+ T-lymphocyte 
was the main laboratory marker studied. A  matched H IV  -ve control 
cohort was studied in parallel.
Method
CD4 cells were stained using dual labelled monoclonal anti­
bodies (Becton Dickinson),followed by red cell lysis and flow 
cytometric analysis (FACScan).
Results % of Cohort
CD4 Band 1988 89 90 91 92 93 94
600+/cmm 29 6 4 1 0 0 0
400-600 47 37 26 5 7 2 2
200-400 24 44 47 33 22 18 2
100-200 0 12 16 30 18 27 18
0-100 0 1 7 31 53 63 28
DEATHS 0 4 5 16 22 28 38
Conclusions
The CD4+ T-lymphocyte count remains the best 
immunological laboratory marker for H IV  disease progression.From 
results above we can see a steady "shift to the left"in  7 years.
The control population showed no significant change. CD8+ and 
H LA DR+ both showed an increase until later stages of AIDS. 
IgA was the only significant immunoglobulin to be elevated. 
Beta 2 microglobulin was also found to be raised and used as 
a disease progression marker. The cohort remains under 
immunological surveilance.
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